Chimeric Antigen Receptor (CAR)-T cell therapy is a promising development in cancer immunotherapy, but method optimization is necessary to produce the cells at scale. In part 1 of this two-part webinar, we will introduce Physiologix XF serum replacement, a new resource for improving the CAR-T expansion process. In this video, we will:
- Introduce Physiologix XF serum replacement
- Share T cell phenotype data from the lab of Dr. Roddy O’Connor of UPENN
Alyssa Master, Ph.D.
Nucleus BiologicsDr. Alyssa Master is the VP of Sales Enablement and Customer Experience at Nucleus Biologics. She is a subject matter expert on cell culture media solutions, primarily on the development of custom cell culture media. Dr. Master has ten years of laboratory research experience, including five years as a lab manager prior to joining Nucleus Biologics. As a biomaterials engineer, her area of expertise is in the field of nanoparticle-mediated drug delivery, particularly for the delivery of cancer therapeutics. During her numerous fellowships, Dr. Master developed a novel targeted drug delivery platform for intravenous delivery of photodynamic therapy agents. Dr. Master earned her Ph.D. in Biomedical Engineering from Case Western Reserve University. Read more
Welcome to Nucleus Biologics, the leader in precision cell culture. My name is Alyssa Master, and I'm the Director of Science and Applications here at Nucleus. One of our focuses is improving the bench-to-bedside process with innovations for the cell therapy market. Today, I will be sharing some exciting new T cell phenotype data from the lab of Dr. Roddy O'Connor, Senior Research Investigator at UPENN Center for Cellular Immunotherapies.
These experiments use the newest addition to our line of media supplements, Physiologix xeno-free human growth factor concentrate. Physiologix was designed with the cell therapy market in mind. It is a fully xeno-free GMP media supplement that is extracted from transfusion-grade donor material. This process gives you the most physiologically relevant media for your cells. For more information on how Physiologix addresses your cell culture needs, please view our other webinars and visit nucleusbiologics.com. Recently, numerous studies have shown that the clinical efficacy of T-cell therapy is tied to the maturation state of the infused cells. Naive-like and central memory T cells have enhanced their therapeutic performance due to their superior expansion capability, greater persistence in vivo, and reduced exhaustion. We identify these populations by using the surface markers CCR7 and CD45RO seen here in the top two quadrants.
Doctor Roddy O'Connor's lab grew bulk human primary T cells in RPMI 1640 containing either 10% FBS as a control or 2% Physiologix. Cells were activated using CD3 and CD28 dynabeads and cultured eight days after for a total of nine days in culture. Flow cytometry was used to examine the cell populations present with gating for CD8-positive live lymphocytes. Within this population, 88% of the cells grown in Physiologix media are favorable naïve-like or central memory T cells compared to only 66% in the control media. This increase in desired phenotypic yield could greatly improve treatment efficacy and could be beneficial for both autologous and allogeneic CAR T-cell therapy.
If you are interested in learning more about how Physiologix performs in T cells or even IPS cells, please stay tuned for future presentations. If you're interested in sampling Physiologix, please email [email protected] or call 858-251-2013 to speak to an application scientist. And, as always, for more information, please visit nucleusbiologics.com. Thank you for your time and we hope you enjoyed learning about Physiologix.